PATENT CLAIM ANALYSIS

Application Number: 15891492
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "012700"]

Abstract:
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Claim (Index 57):
The method of  claim 56 , wherein said cardiovascular disease is selected from coronary artery disease, heart attack, arrhythmia, heart failure, cardiomyopathy, and vascular disease.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 88.0
- Lexical Diversity: 1.40476
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13774349', '15386347', '15239277', '13212101', '14152302']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7807299177353259
- 35 USC 102 Novelty (BERT): 0.5640103151918141
- Combined Prediction Score: 0.7590579574809747
- Mean Citation Score: 442.75909400000006
- Max Citation Score: 465.6355
- Similarity Product: 310.29298215037585

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test